The FDA has granted accelerated approval to golodirsen injection (Vyondys 53, Sarepta Therapeutics) to treat patients with Duchenne muscular dystrophy (DMD) who have confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.
New research reveals how aging weakens immune responses to RSV in older adults, increasing severity and hospitalization risks.
This new generic will impact both oncology and community pharmacists.
A new study reveals that heart failure patients with implantable devices are more likely to receive the pneumococcal conjugate vaccine 13, impacting vaccination rates and…
New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.
In patients with synchronous metastatic colorectal cancer treated without curative intent, high low-density lipoprotein (LDL) cholesterol was associated with poor survival.
A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.
The regimen, which consists of durvalumab and Bacillus Calmette-Guerin, offers new hope to patients with high-risk non-muscle-invasive bladder cancer.
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.
PharmStart empowers pharmacy technicians to pursue their education with tuition-free prerequisites, addressing barriers to entering pharmacy school.
